Janus kinase inhibitors: Mechanisms of action

Australian Prescriber

Volumn 37, Issue 5, 2014, Pages 154-157

  Kubler, Paul ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Baracitinib; Cytokines; Ruxolitinib; Tofacitinib

Indexed keywords

BARICITINIB; CYTOKINE; CYTOKINE RECEPTOR; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RUXOLITINIB; STAT PROTEIN; TOFACITINIB;

ANEMIA; ARTICLE; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; LEUKEMIA; LYMPHOMA; MUTATION; NEUTROPENIA; POLYCYTHEMIA VERA; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

EID: 84929921394     PISSN: 03128008     EISSN: 18393942     Source Type: Journal    
DOI: 10.18773/austprescr.2014.061     Document Type: Article

References (11)

1. O’Shea J., Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
2. Leonard WJ, O’Shea JJ. Jaks and STATS: biological implications. Annu Rev Immunol 1998;16:293-322.
3. O’Shea J., Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2:ii111-5.
4. Laurence A, Pesu M, Silvennoinen O, O’Shea J. JAK kinases in health and disease: an update. Open Rheumatol J 2012;6:232-44.
5. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010;116:1528-38.
6. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010;17:584-96.
7. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
8. Kwatra SG, Dabade TS, Gustafson CJ, Feldman SR. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol 2012;11:913-8.
9. Refusal of the marketing authorisation for Xeljanz (tofacitinib). European Medicines Agency; 2013. www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002542/WC500146629.pdf [cited 2014 Aug 29]
10. Walker J, Smith M. Experimental and clinical pharmacology. Janus kinase inhibitors in rheumatoid arthritis: clinical applications. Aust Prescr 2014;37:158-60.
11. Bazargan A, Tam C. Experimental and clinical pharmacology. Janus kinase inhibitors in myeloproliferative neoplasms: clinical applications. Aust Prescr 2014;37:161-2.